ArticleNature biotechnology2025
KATMAP infers splicing factor activity and regulatory targets from knockdown data.
Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNA splicing and cardiovascular disease: a guide for cardiologists.European heart journal · 2026Review
- Evaluating splicing factor and kinase network crosstalk through global phosphoproteomics.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Typical RNA sequencing (RNA-seq) experiments uncover hundreds of splicing changes, reflecting underlying changes in splicing factor (SF) activity. Understanding how SF activity influences transcriptomic variation requires elucidating how each SF impacts splicing. Here, we present an interpretable regression model, KATMAP, which models splicing changes throughout the transcriptome by analyzing changes in SF binding and the resulting alterations in RNA processing. To learn a regulatory model, KATMAP requires SF perturbation RNA-seq data and the SF's binding motif as inputs, returning a description of the SF's position-specific regulatory activity and predicted targets. The KATMAP software includes models pretrained on ENCODE SF knockdown data. Learned KATMAP models can be applied to predict SF regulation and cis-elements at individual exons, which can guide the design of splice-switching antisense oligonucleotides. KATMAP can also interpret RNA-seq data by uncovering the factors responsible for transcriptomic changes, distinguishing direct SF targets from indirect effects and inferring relevant SFs from clinical RNA-seq data.
Identifiers
41188645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.